<DOC>
	<DOCNO>NCT02941783</DOCNO>
	<brief_summary>The objective study collect post-marketing information safety efficacy Kovaltry routine clinical practice .</brief_summary>
	<brief_title>Drug Use Investigation Kovaltry Hemophilia A Patients</brief_title>
	<detailed_description>This company-sponsored study single-arm , prospective , observational study hemophilia A patient administered Kovaltry . 200 case plan register safety analysis set three-year period . Within 200 case , 50 case less 12 year old plan register . Target population hemophilia A patient . The treatment perform base product label Japan . The standard observation period two year .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male female hemophilia A patient . Patients decision treat Kovaltry determine prior enrollment study . Patients participate investigational program intervention outside routine clinical practice . Patients additional diagnosis bleeding/coagulation disorder hemophilia A .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kovaltry</keyword>
	<keyword>hemophilia A</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>